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Abstract
The endothelium lies in a strategic anatomical position between the circulating blood and the
vascular smooth-muscle cells. It is a source of vasodilators such as nitric oxide, prostacyclin,
and hyperpolarizing factor as well as heparin-like substances and other molecules with anti-
proliferative properties. These effects of endothelial cells may explain why platelets and
monocytes usually do not adhere at the blood vessel wall. However, under pathological condi-
tions, endothelial dysfunction occurs and significantly contributes to the increase of platelet-
-vessel wall interaction, vasoconstriction, pro-inflammation, and proliferation. Under these
conditions, endothelium-dependent vasodilation is reduced, and endothelium-dependent con-
strictor responses are augmented. Upon vessel wall injury, the platelets rapidly adhere to the
exposed sub-endothelial matrix, which is mediated by several cellular receptors present on
platelets or endothelial cells and various adhesive proteins. Subsequent platelet activation
results in the recruitment of additional platelets and the generation of platelet aggregates, so
forming a stable platelet plug. Therapeutic strategies aimed at improving or preserving en-
dothelial function therefore may be promising in terms of preventing and treating coronary
artery disease. Diagnostic modalities for assessing endothelial function should allow for the
early detection of vascular endothelial dysfunction before the manifestation of serious adverse
vascular disorders. (Cardiol J 2011; 18, 4: 352–363)
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Introduction
Cardiovascular disease (CVD) as a result of
atherosclerosis is a well-known  and significant con-
tributor to morbidity and mortality worldwide, af-
fecting 80 million people aged 20 and over in the
United States in 2006. In the United States in 2006,
approximately 7,095,000 inpatient cardiovascular
operations and procedures were performed. The
estimated cost (direct and indirect) in the US for
CVD in 2009 was $475.3 billion. Furthermore, in-
creased risk is associated with advancing age; in
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2005, more than 150,000 Americans who died from
CVD were younger than 65 [1]. Given an average
US life expectancy of about 77 years, these deaths
are deemed premature, and necessitate advance-
ments in the treatment and prevention of CVD.
Among the 80 million people aged 20 plus in
the US affected by CVD from atherosclerosis, pe-
ripheral arterial disease affects about 8 million of
them and has risk factors similar to those of coro-
nary artery disease [1], probably due to homologous
origins of disease, further underscoring the need to
address the notion of endothelial cell dysfunction
— the apparent source of CVD. Major advances
have been made in understanding the early mecha-
nisms of endothelial dysfunction. Given the com-
plexity of the genetics, molecular mechanics, and
physiology of this disease, it is important to con-
tinue to pursue a deeper understanding of its intri-
cacies. Such research will likely lead to prevention
strategies as early in the disease process as possi-
ble. This would be a far more cost-effective alter-
native to treating already established CVD. Certain-
ly, any advances in treatment and prevention stra-
tegies against CVD will greatly benefit our
healthcare system.
Endothelial cell dysfunction is a hallmark of the
early development of atherosclerosis. While many
medications that reduce the risk of CVD exist, in-
cluding statins, purified fish oils, ACEIs/ARBs, and
thiazide diuretics, “all the major risk factors for athe-
rosclerosis have been associated with impaired
nitric oxide activity,” [2] which is a primary mark-
er for endothelium dysfunction [3, 4].
This, combined with the rise of flow-mediated
dilation as an indicator of a patient’s nitric oxide (NO)
bioactivity, can open the door to identifying patients
with early endothelium dysfunction [4]. These pa-
tients would likely be more susceptible to various
forms of CVD, so early identification is highly bene-
ficial. This practice can pave the way to testing
a growing array of medications aimed at correcting
early endothelial cell dysfunction. It is all but cer-
tain that such correction will lead to longer term risk
reduction and improved clinical outcomes.
Reduced bioactivity of NO is the current bench-
mark for recognizing endothelial cell dysfunction
[3]. However, despite NO’s predictive value, many
other biological molecules are responsible for en-
dothelial cell homeostasis, giving a wide variety
of potential drug targets (Fig. 1). Identifying and un-
derstanding key biological markers/mediators in-
volved in the pathophysiology behind endothelium
dysfunction should ultimately lead to methods of
treating or preventing the early onset of atheroge-
nesis. The literature shows that endothelial cell dys-
function and plaque formation is characterized by
a balance shift featuring decreased vasodilatory,
thrombolytic, anti-inflammatory, and anti-coagulant
molecules (of which NO is arguably the most sig-
nificant) relative to their pro-coagulant, vasocon-
strictive, and thrombotic counterparts [3].
This review is a summary of some potential
drug targets geared toward stimulating the anti-
atherogenic properties of the endothelium, cen-
tered on some of the key biological functions of the
endothelial cell. Table 1, adapted from Blann et al.
[2], identifies key components of the endothelium,
some of which are discussed in this review. In ad-
dition, there are other molecules that are pro-
atherogenic and are not directly related to the en-
dothelium (such as angiotensin II, thrombin, plas-
min, and fibrin) that are not listed in Table 1. The
anti-atherogenic column in Table 1 lists molecules
that are of an anti-coagulant, anti-thrombotic, anti-
-inflammatory, anti-adhesive, or vasodilatory nature.
The opposite is true of the pro-atherogenic column.
The molecules in either column should not be con-
sidered healthy, or unhealthy, because pathologi-
Table 1. Types of anti- and pro-atherothrombogenic molecules in endothelium (adapted from Blann et al. [2]).
Anti-atherothrombogenic mediators Pro-atherothrombogenic mediators
Cell surface molecules Thrombomodulin Tissue factor
Protein C Binding sites for coagulation factors
Heparin and heparin sulfate
Ectonucleotidases
Tissue factor pathway inhibitor
Endothelial estrogen receptor-alpha (ERa)*
Released molecules Nitric oxide Thromboxane A2
Prostacyclin Platelet activating factor
Tissue plasminogen activator (t-PA) Von Willebrand factor
t-PA binding sites    Endothelin
*ERa plays a key role in the E2-induced prevention of endothelial dysfunction after ischemia/reperfusion [60]
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cal conditions tend to arise only from irregular ex-
pression of these molecules. It is important to note
that factors in the ‘pro-atherogenic’ category are of
great physiologic importance for normal health, and
that complete inhibition of any of these factors will
likely have adverse results. However, these factors,
in certain cascades, can play atherogenic roles in
a dysfunctional endothelium. Furthermore, some
anti-atherogenic molecules, which lyse clots, may
play a role in triggering thrombosis in advanced
lesions.
Organic nitrates and innovative nitric
oxide donors for the endothelium
Organic nitrates such as isosorbide dinitrate
(ISDN) or isosorbide mononitrate (ISMN) are com-
monly used in the treatment of stable angina and
the improvement of exercise tolerance in the clini-
cal setting. However, little attention has been paid
to the great potential that may be derived from re-
cent advances in the understanding of nitrate func-
tion. For example, nitrates have been identified that
can increase NO production, and perhaps slow or
prevent the progression of atherosclerosis, unlike
traditional nitrates used for stable angina. Such
molecules may be important given the fact that rou-
tine administration of organic nitrates is typically
associated with tachyphylaxis, decreased NO bio-
availability, and the development of endothelial cell
dysfunction [5]. This is typically caused by the gen-
eration of reactive oxygen species (ROS), general-
ly produced by the resultant superoxide anion from
the nitrate metabolic pathway [6, 7]. ROS inhibit
mitochondrial aldehyde dehydrogenase (ALDH-2),
which is a primary enzyme for the metabolism of
certain nitrates. Consequently, long term repetitive
treatment with nitroglycerin, versus ISMN and
ISDN, is more associated with worsened endothe-
lial cell-dependent vasodilation and a decrease in
NO bioavailability [5, 7]. However, among all orga-
nic nitrates, repeated long term administration is
still linked to nitrate tolerance.
While nitrate-free intervals generally decrease
or prevent long term nitrate tolerance [7], the con-
trol of ROS is still of significant pharmacologic im-
portance, and has been a focus of recent research
regarding organic nitrate function. Compounds pos-
sessing three nitrate groups go through a mitochon-
drial biotransformation that is not undergone by
compounds with two or fewer nitrate groups. This
biotransformation is associated with the increased
generation of ROS [6].
This has led to ISMN and ISDN being preferred
in clinical practice for the long-term treatment of
stable angina since they do not seem to significant-
ly stimulate the production of ROS [6]. This is like-
ly due to their metabolism being through the non-
-mitochondrial ‘low affinity pathway’ in tissues [8].
However, Dragoni et al. [6] have recently shown
that pentaerithrityl tetranitrate, typically avoided
due to its mitochondrial metabolism, exhibits an
additional antioxidant effect and an ability to stimu-
late protective genes that code for the generation
of heme-oxygenase-1 and ferritin. The authors hy-
pothesize that these genes play a role in the es-
tablishment of endothelial cell ‘pre-conditioning’
[6]. Pre-conditioning means that tissues, such as the
myocardium, undergoing transient periods of is-
chemia, can become resistant to periods of severe
ischemia. This phenomenon was shown to be con-
sistent in the endothelium by Zahler et al. [9], and
is another area of great interest and therapeutic
potential.
On a similar front, dietary nitrite is making
a return appearance. Although in the past nitrites
have been associated with negative consequences,
Figure 1. Hemostasis of vascular endothelium: endo-
thelium as an organ represents 1–6 × 1013 cells mono-
layer, weighs 1 kg, covers six tennis courts, and main-
tains hemostasis of various physiological functions.
Modulator of vascular tone via nitric oxide, prostaglan-
din I2 (PGI2, prostacyclin), endothelin and various recep-
tors. Regulator of hemostasis via anti-thrombotic, pro-
-thrombotic mediators. Modulator of inflammation via
pro- and anti-inflammatory mediators.
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a recent extensive report showed the presence of
many beneficial effects of nitrites on the endothe-
lium [10]. In rats with micro-vascular inflammation
induced by a high cholesterol diet, nitrite supple-
mentation in water proved protective against en-
dothelial dysfunction. Nitrite ingestion is involved
in returning C-reactive protein levels back to nor-
mal in these mice and the preservation of BH4, a re-
dox enzyme that is involved in NO formation. Nitrite
is also known to be depleted in hyper-cholesterole-
mic states. Given this, and the abundance of nitrite
in vegetables (where they are associated with ‘heart
health’), and given the hypothesis that N-nitrosamine
formation is the true carcinogenic worry, a re-eva-
luation of nitrite supplementation seems sensible
[10]. Perhaps nitrite given as a ‘cocktail’ with com-
pounds that inhibit N-nitrosamine formation could
provide long-term protection of the endothelium
without adverse consequences.
Thrombomodulin
Thrombomodulin (TM) is a 100 kDa membrane
protein that is expressed on the surface of endo-
thelial cells. It is involved in maintaining the balance
between the anti-coagulant and pro-coagulant pro-
perties of the endothelium [11, 12]. Each endothe-
lial cell typically contains 50,000–100,000 TM mo-
lecules [13]. TM possesses a large number of anti-
atherogenic functions. Among these are its activation
of anti-coagulant protein C via formation of the
thrombin-TM complex, and its facilitation of throm-
bin–anti-thrombin complex formation via its chon-
droitin sulfate moiety [14, 15]. TM is also respon-
sible for the activation of thrombin activatable fi-
brinolysis factor which is also being examined for
its anti-inflammatory properties [15]. TM is a multi-
domain peptide that can be recombinantly ex-
pressed in various forms with a large variety of func-
tional activities [16, 17]. Given TM’s wide range of
anti-coagulant functions, it is unsurprising that lo-
cal TM deficiencies have been linked to thrombo-
sis and atherogenesis in animal models [14]. The
functions of TM, and the physiologic consequences
of localized TM deficiency, clearly underscore its
role in the prevention of plaque formation. [14]. In
addition to this, TM is sub-normally expressed in
endothelial cells lining atherosclerotic plaques [14,
18], and  loss of TM activity in vein grafts is linked
to early thrombosis [19].
Given this information underscoring the physio-
logical consequences of lacking TM, the obvious
follow-up question is: what would be the result of
hyper-expression of TM along cells in the endo-
thelium? Furthermore, since TM is less prevalent
in endothelium lining atherosclerotic plaques, the
next question is: what is TM’s role in the stabiliza-
tion of plaques? While treatment of atherosclerotic
plaques would ideally involve reversal and remo-
val of the fatty streak, perhaps stabilizing a slightly
occluded vessel could be a less invasive approach
to preventing plaque growth and minimizing the risk
of occlusive thrombosis.
Many genes have been identified as associated
with changes in TM function and therefore clinical
manifestations of disease. These genetic polymor-
phisms tend to be associated with an increased risk
of myocardial infarction or atherosclerosis, and are
listed in Weiler and Isermann [14]. These clinical
correlations match up with the notion that loss of
TM or inactivation of endothelial TM can lead to
vascular complications. Loss of TM expression on
the endothelial cell membrane can occur via multi-
ple mechanisms. These include oxidation of func-
tional domains of TM, any trigger of large amounts
of cytokines — generally from sufficient endothe-
lial cell injury — which in turn suppress its gene
transcription, or neutrophil-triggered release of
soluble TM [14, 15].
These facts refine the previous questions:
would increased cellular TM expression make the
endothelium more resistant to these inflammatory
response cascades? Would such hyper-expression
of TM lead to a more non-reactive endothelium that
is more resistant to the development of atheroscle-
rotic lesions? Or, would this lead to the endotheli-
um having a decreased ability to repair vascular in-
jury? Furthermore, this information underscores the
need to identify the genetic targets that control TM
expression, so that they can be modified in order to
design experiments to answer these questions.
In 2004, a new gene transfer method using
a “ligand-facilitated transfer of the cationic liposome:
TM gene complex” was used to induce the over-
expression of TM in rat inferior vena cavas [19].
This over-expression was induced prior to excision
and vein graft operation. Amazingly, under reduced-
flow conditions of venous endothelium, over-ex-
pression of thrombomodulin was achieved by this
high-efficiency method. This translated to a great-
er thrombo-resistance (i.e. less clotting induced by
thrombin) in the grafts with over-expressed TM
versus control groups, thus preventing acute graft
failure [19]. These results, combined with full
length TM’s ability to inhibit smooth muscle cell
proliferation, make it a good candidate for in vivo
studies related to operative occlusion prophylaxis
[20]. TM over-expression can perhaps protect
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against stent failure and a variety of graft failures.
While experimentation is currently focused on
venular endothelium TM, the advent of even high-
er efficiency gene transfer techniques (potentially
used under normal flow conditions) could open up
a world of clinical opportunities with regard to ar-
terial endothelium TM.
Soluble thrombomodulin is another interest-
ing factor with potential for controlling atherogen-
esis/thrombosis. Soluble TM appears to be a cleaved
fragment of the membrane TM that is released into
the bloodstream via ‘neutrophil-elastase-dependent
proteolytic release’ [13, 14]. Soluble TM is known
to be elevated in a variety of disease states associa-
ted with endothelial cell injury [21]. This form of
TM still retains significant amounts of cofactor/bio-
logic activity relative to cellular TM. Soluble TM
still has the ability to inhibit fibrinolysis, and some
fragments retain the ability to activate protein C at
30–50% of the affinity of cellular TM. Variations in
the types and sizes of soluble TM fragments also
seem to produce drastic differences in functional
activity [21]. This variability is likely due to an ar-
ray of expressions of its chondroitin sulfate (CS)
moiety among fragments [16]. The chondroitin sul-
fate moiety is responsible for increasing TM’s abili-
ty to inhibit thrombin, and furthers the binding of
anti-thrombin III to thrombin. TM possessing the
chondroitin sulfate moiety (at full length) is more
prevalent in arterial endothelial cells than in venous
endothelial cells [16]. Another example of different
functional fragment activity involves the lectin do-
main. The lectin-like domain is associated with anti-
inflammatory properties, while showing no anti-
coagulant or fibrinolytic actions. It has been shown
to protect endothelial cells in certain destructive
conditions, and disrupts monocyte adhesion to ac-
tivated endothelium [14, 22].
Several different soluble TM fragments have
been identified, found in different concentrations
among different cardiac risk disease states [21].
Isolating and understanding the different structure-
-function relationships among soluble TM frag-
ments could lead to the identification of the most
therapeutically beneficial components for correlat-
ing disease states. For instance, it is important to
identify the beneficial or adverse effects of routine
administration of rTM consisting of only the lectin-
-like domain. Thus far, it has been shown to reduce
inflammation in mouse models, and seems to hold
promise in various inflammatory disorders, includ-
ing arthritis [22]. Perhaps these anti-inflammatory
properties could provide long-term risk reduction
by reducing micro-vascular inflammation in CVD.
Other manipulations could provide a safer and
more specific alternative for anti-coagulant thera-
pies in the setting of acute coronary syndromes.
While the current paradigm is centered on unfrac-
tionated and low molecular weight heparins, bleed-
ing complications are still of significant concern.
However, manipulated soluble TM fragments can
be explored as a potentially safer and comparably
efficacious alternative. For example, the soluble-
-TM-thrombin complex still exhibits the anti-coa-
gulant property of protein C activation. In addition,
some soluble and recombinant TM does not have
the chondroitin sulfate moiety, which directly in-
terferes with its abilities to activate protein C and
facilitate the formation of the thrombin–anti-throm-
bin complex [14, 16]. Perhaps these fragments can
provide a therapeutically beneficial balance of ac-
tivity. Different concentrations of these fragments
may exhibit safer degrees of anti-coagulation while
maintaining efficacy.
In short, purifying and experimenting with va-
rious TM domain fragments may unlock an entirely
new class of acute care blood thinners or anti-in-
flammatory agents.
Tissue factor and
tissue factor pathway inhibitor
Tissue factor is a transmembrane protein that
plays a significant role in the extrinsic pathway of
the coagulation cascade. It is expressed on various
immune cells and smooth muscle cells, and certain
conditions cause it to be expressed in endothelial
cells. Tissue factor is abundant in atherosclerotic
lesions, and is associated with an increased risk of
thrombus formation within those lesions. It is re-
gulated by tissue factor pathway inhibitor (TFPI),
which exerts its effects via factor Xa inhibition, and
is predominantly seen in the endothelial cells of the
microvasculature [23].
There are a variety of TFPIs, and one of the
most clinically promising versions is active-site-
-inactivated recombinant factor VIIa. Its mechanism
of action is competitive inhibition of factor VIIa to
prevent binding to tissue factor. Inhibition of throm-
bosis without prolonged bleeding time has been ob-
served in animal models using this inhibitor [23].
Additionally, monoclonal antibodies against tissue fac-
tor provide a variety of beneficial effects, including
reduction in thrombin-mediated inflammation [23].
A recent trial has demonstrated that thrombin
is a key molecule for initiating tissue factor in hu-
man umbilical vein endothelial cells. This mecha-
nism is further enhanced by plasmin treatment. The
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study concluded that plasmin’s proteolytic activity
was needed to create this increased expression of
tissue factor. While other explanations are possi-
ble, it is likely that plasmin increases local tissue
factor by cleaving TFPI [24]. Should this be true,
the next question is whether an elevated level of
TFPI would be completely degraded by the same
level of enzyme activity, or if plasmin’s activity is
of limited capacity.
It appears that plasmin activity can be overrid-
den, since recombinant TFPI inhibits thrombus for-
mation and fibrin deposition in injured arterial seg-
ments (two events dependent on thrombin activat-
ing TF) [23]. Increased TF activity in atherosclerotic
plaques is associated with conditions more condu-
cive to thrombosis [23]. Perhaps increased TFPI
levels locally can provide protection against throm-
bus formation when performing stent operations.
This opens the door to therapeutic options similar
to those of thrombomodulin. Perhaps high-efficien-
cy gene transfer over-expression of TFPI in athe-
ro-prone segments of endothelium can correlate
with better clinical outcomes during stenting or
angioplasty.
With regard to tissue factor itself, some tissue
factor polymorphisms are associated with poor clini-
cal outcomes in CVD. The +5466A>G polymor-
phism has been shown to influence not only the risk
of cardiac death, but also the effect of statins on
thrombin formation [25]. Undas et al. [25] identi-
fied a certain polymorphism that may be linked to
variable pleiotropic effects in statins, aside from
cholesterol lowering. This study is the first step on
a path toward potentially identifying optimum drug
regimens based on patient genotype, and may be
important in the setting of personalized medicine
approaches in the future by aiding the risk stratifi-
cation of patients. Further identifying and charac-
terizing high risk polymorphisms with regard to
factors related to the endothelium will be crucial in
the design of new patient-specific therapies. Tis-
sue factor, and its pathway inhibitor, is certainly of
interest for future pharmacogenomic approaches.
Endothelial lipase and HDL modulation
by tissue factor pathway inhibitor
Endothelial lipase (EL) is an intriguing lipid
hydrolyzing enzyme that robustly influences high
density lipoprotein (HDL) metabolism [26], but the
health implications of this modulating activity in
humans are unknown. It is the most recently discove-
red member of the lipase gene family that includes
lipoprotein lipase and hepatic lipase. In contrast to
those other two lipases, EL is produced by endothe-
lial cells. EL activity is increased in the midst of in-
flammatory states as reflected by its upregulation by
proinflammatory cytokines. It is  interesting that EL
has been found to hydrolyze HDL, and that EL ac-
tivity may explain the inverse relationship that ex-
ists between inflammatory states and levels of HDL
[27]. Although it is possible that downregulating EL
will lead to increased HDL and reduced risk for CVD,
the health implications of modulating EL are un-
known. However, if a therapeutic agent reduces EL
and inflammatory cytokines while increasing HDL,
this would suggest that the agent possesses strong
therapeutic potential. The benefits of such metabol-
ic regulation by this novel agent await investigation
of the cardiovascular effects on humans in states of
health and disease.
Prostacyclin
Prostacyclin is another molecule endogenous
to the endothelium that is responsible for vasodila-
tory and protective actions on the endothelium. In-
hibitors of prostacyclin formation or activity will like-
ly inhibit normal endothelial function, and conse-
quently open the door to atherosclerotic plaque
formation [28]. Increased oxidative stress via su-
peroxide anion formation leads to peroxynitrate
formation [8]. Peroxynitrate is known to inhibit
prostacyclin synthase (PGI-S) [28]. Given that pros-
tacyclin is vital in controlling vasodilation and in-
hibiting thrombus formation [3, 29], this suggests
a mechanism for how oxidative stress can make the
endothelium more prone to developing atheroscle-
rotic lesions. In addition, the notion that various li-
pid peroxides inhibit PGI-S further supports the role
of decreased prostacyclin protection in atheroscle-
rosis [28], because oxidant injury is linked to both
lipid peroxide formation and atherosclerosis [30].
The role of prostacyclin has been established
as vital to a healthy endothelium, and so the deve-
lopment of prostacyclin analogs followed. Prostacy-
clin analogs have already shown degrees of effica-
cy in disease states including pulmonary arterial
hypertension, Buerger’s disease, and critical limb
ischemia [28, 31]. More recently, it has been shown
that iloprost, a prostacyclin analog, has the ability
to increase circulating endothelial progenitor cells
(EPCs) in patients with critical limb ischemia [31].
Following up on data from previous studies show-
ing improvement in ulcer healing, level of pain, and
delayed amputation, the authors decided to uncov-
er the potential mechanism behind these clinical
benefits. Based on the evidence that iloprost can
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activate many pro-angiogenic genes, and that clini-
cal benefits in critical limb ischemia come from
more than anti-platelet and vasodilatory actions, the
authors set out to determine iloprost’s effect on
EPCs. The dosing rate for the IV infusion was
a median of 1.2 ng/kg/min for six hours to prevent
hypotension and tachycardia. Of the 23 enrolled
patients, 14 had reduced pain and the other nine had
stabilized pain. EPC levels were increased from
a median of 13,812/mL pre-treatment versus 23,739/
/mL post treatment. These results demonstrate that
iloprost does seem to increase EPCs, an effect to
which the authors attributed the positive clinical re-
sponse as reflected by pain reduction and delayed time
to amputation consistent with previous studies.
The authors acknowledged that the data is short
term and may not correlate with long-term outcomes,
and that the population sample was very small. How-
ever, given the data supporting the ability of EPCs
to promote angiogenesis, longer term trials are war-
ranted to clarify iloprost’s benefit in a variety of vas-
cular conditions [31]. Iloprost is also associated with
good tolerability in recent trials involving limb is-
chemia [31, 32]. Concordantly, it seems appropriate
to study tolerable doses of iloprost for angiogenic
benefits in other patient populations at high risk for
vascular disease. Future research may focus on the
development of an oral or SQ formulation suitable
for outpatient therapy, and investigations regarding
that form of dosage would affect overall atheroscle-
rotic plaque formations in high risk patients.
With the mechanistic potential for endothe-
lium preservation, and this newfound efficacy data
in peripheral ischemic disease, perhaps the next
stage would be to identify the most tolerable analogs
and test them in clinical trials. Circulating endothe-
lial progenitor cells could indicate the severity of vas-
cular disease. Increased EPCs of normal functio-
nal capacity correlate to a lower risk for developing
atherosclerotic lesions, and EPCs are linked to the
regeneration of new blood vessels [5, 31].
Moreover, work by He et al. [33] has demon-
strated that the angiogenic properties of EPCs are
dependent on the biosynthesis of prostacyclin.
Characterizations of the functions of iloprost on
EPC function have helped elucidate some of the
mechanisms and pathways by which EPCs function
to proliferate and promote angiogenesis [33]. Con-
tinuing research along the lines of prostacyclin ana-
logs with regard to EPC function will likely lead to
classification of more specific therapeutic targets in
EPCs; this should ultimately lead to new drug class-
es for the prevention and treatment of atheroscle-
rotic vascular diseases.
Ligustrazine derivatives
Recent publications have discussed various
forms of ligustrazine derivatives as novel compounds
for use in the protection of endothelial cells. While
these are not endogenous compounds in the body,
they deserve attention for anti-oxidant protection of
the endothelium. The studies examined the effects
of various derivatives of ligustrazine on ECV-304 and
HUVEC cells. While ligustrazine has a wide variety
of pharmacological uses, the compound has been
more recently noted to have protective effects on
injured vascular endothelial cells [34, 35].
The first study evaluated a variety of 2-acy-
loxymethyl-3,5,6-trimethylpyrazine derivatives.
Some compounds exhibited the ability to protect
HUVEC cells from hydrogen peroxide (oxidative
stress) damage, while others stimulated the proli-
feration of normal cells while being unable to pro-
tect the cells from damage [35].
In the second study, ECV-304 cells were used
instead of HUVECs. It was found that one particu-
lar derivative produced a greater protective effect
against hydrogen peroxide damage of endothelial
cells versus the other derivatives or original ligus-
trazine. The derivative, which included the bisphe-
nylmethyl group on the methyl position of ligustra-
zine, provided the lowest EC50 for ECV-304 pro-
tection against hydrogen peroxide damage.
The third part of these experiments included
acylpiperazinyl derivatives. 2-(4-salicyloyl-1-pipera-
zinmethyl)-3,5,6-trimethylpyrazine (compound
E33) was determined to have the most beneficial
effect, again on ECV-304 cells exposed to hydro-
gen peroxide [36]. Structure-activity relationships
are discussed in each of the respective articles, and
biological assays are in progress to further under-
stand the effects of these compounds. This is an
interesting class of molecules derived from a tradi-
tional Chinese medicine herb, and may perhaps
pave the way toward new agents in preserving the
integrity and balance of the endothelium. Consi-
dering that compounds in each of the three studies
were found to protect against oxidative stress, cou-
pled with the physiological role of oxidative stress
on atherogenesis and NO dysfunction, it is easy to
see why these are attractive compounds.
Adiponectin
Shibata et al. [37] recently reviewed adiponectin
and CVD. Adiponectin is a plasma protein derived
from adipose tissue. It is typically found in human plas-
ma at concentrations of 3–30 mg/mL. When this pro-
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tein is inadequate in patients with existing cardiovas-
cular conditions, the result is increased incidence of
adverse events. For example, low plasma adiponec-
tin concentration is found in patients with acute coro-
nary syndrome, while higher levels are associated
with decreased myocardial infarction in healthy
males. Another example is that higher serum adi-
ponectin levels in patients with peripheral arterial
disease correlate with better maximum walking dis-
tances and other positive signs. Furthermore, weak
association with better cardiovascular outcomes in
end-stage renal patients was shown in a recent meta-
analysis. Most clinical evidence still shows the clear
cut benefit of higher adiponectin levels in general
CVDs [37].
Despite its semi-controversial clinical benefits,
adiponectin has shown some evidence in animal
models with regard to endothelium preservation
and reduced levels of atherosclerosis. Adiponectin
has been shown to play roles in angiogenesis, EPC
levels, NO production by endothelial cells, and in
the prevention of endothelial apoptosis in in vitro
models [37]. Adiponectin also plays a stabilizing role
in the endothelium by decreasing the expression of
certain cell adhesion molecules via NFkB suppres-
sion. Lastly, its role in endothelium health is fur-
ther established by its ability to reduce reactive
oxygen and reactive nitrogen species (thus preserv-
ing NO function) in endothelial cells.
Adiponectin exerts its effects apparently via
AMP-activated protein kinase. Various forms of
adiponectin translate to different physiological ef-
fects. Primarily, the high molecular weight form is
responsible for endothelial cell functions, while the
other trimer form exerts greater effects on myo-
cytes [38].
Shear stress and its mechanical
stimulation of genetic and cellular targets
There are many arguments in favor of the ben-
efits of exercise to reduce atherosclerotic risk. The
mechanism behind this is likely related to the con-
cept of shear stress on the endothelium, and how it
regulates the function of molecules related to en-
dothelial cell homeostasis.
Shear stress is essentially the drag force of
blood rushing parallel along the vessel wall. This
force is crucial in maintaining the anti-atherogenic
state of the endothelium. Shear stress also helps
explain why only certain parts of the human vascu-
lature are susceptible to atherosclerotic plaque for-
mation via endothelial cell dysfunction. This sus-
ceptibility is from areas of low or oscillatory shear
stress that shifts the balance of the endothelium
more toward a pro-atherogenic and pro-inflamma-
tory state. Shear stress is associated with the re-
gulation of genes that control endothelial nitric oxi-
de synthetase (eNOS) and TM [39–41]. These two
molecules play key roles in maintaining an anti-co-
agulant and anti-inflammatory state in the endo-
thelium [15]. Additionally, areas of low shear stress
are shown to have lower expression of eNOS and
are vulnerable to the development of atherosclero-
sis [41, 42]. Two key transcription factors, Nrf2 and
KLF2, have been identified as responsible for about
70% of the expression of endothelial cell genes in-
duced by shear stress [40]. It has been suggested
that developing inducers of these molecules may
provide the ability to stimulate an anti-inflammato-
ry/anti-coagulant state in areas of low or oscillatory
shear stress that are normally prone to atheroscle-
rosis [40, 41]. While the physiologic consequences
of such inducers are still unknown, developing these
compounds could lead to a greater understanding
of the pathway, and perhaps to the development of
clinically important compounds.
Sirt-1 genetic modulator
Other methods for regulating the expression
of eNOS, and thereby increasing NO output, include
examination of the Silent information regulator
class of proteins (Sirt). Sirt-1 is a deactylating pro-
tein covered extensively in a recent review by Po-
tente and Dimmeler [43], as a novel target for main-
taining endothelial cell homeostasis. To summarize,
this protein is responsible for the regulation of many
transcriptional factors including Foxo1, p53, and
nuclear factor LXR in hepatocytes. Most relevant
to the topic we are discussing is its regulation of
eNOS. Sirt-1 is thought to regulate eNOS expres-
sion based on some key pieces of evidence. The
administration of resveratrol, which activates Sirt-1,
has also been shown to increase the expression of
eNOS [43]. In addition, Sirt-1 inhibition in the ar-
terial endothelium inhibits endothelium-depen-
dent vasodilation. It has been shown that Sirt-1 pro-
motes the output of NO via the deacetylation of
eNOS [44]. Furthermore, caloric restriction, which
lowers blood pressure in healthy individuals, has
been shown to promote the deacetylation of eNOS
in mice. Putting this all together, Sirt-1 is a deacty-
lating regulator of the expression of eNOS [43, 44].
Sirt-1 may also play roles in terms of vascular
growth, removal of cholesterol from peripheral tis-
sues, improvement of insulin sensitivity, and endo-
thelial senescence [43].
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Essentially, Sirt-1 can control risk factors
across the board with respect to diabetes, high cho-
lesterol, and aging effects in the body. On the down-
side (and potential upside), Sirt-1 activity is en-
hanced in certain tumors, which may be a pitfall to
chronic administration of a Sirt-1 activator (yet
paves the way for new anti-tumor agents). Conse-
quently, it seems simultaneously attractive yet po-
tentially hazardous as a drug target for disease [43].
While Sirt-1 activity suppresses cancer in breast
and colon cells, it appears that Sirt-1 also is respon-
sible for the maintenance of prostate cancer and
certain epithelial cell cancers [45]. As noted by Kim
and Um [45], a better understanding of Sirt-1’s dif-
ferent mechanisms in these cancer cells versus its
anti-aging properties would pave the way to a whole
new avenue for targeting atherosclerosis and relat-
ed chronic diseases.
Resolvins and lipoxins
in endothelial dysfunction
Endothelial-leukocyte interactions trigger
a novel and interesting set of inflammation-resol-
ving, potent lipid mediators known as lipoxins and
resolvins.
Lipoxins are metabolites of arachidonic acid,
and resolvins are metabolites of the omega-3 fatty
acids, eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA). Through a mechanism that
is not yet fully understood, they are known to bring
an end to inflammatory processes occurring within
the endothelium. Aspirin seems to play a key role
in the intercellular interactions leading to the for-
mation of these compounds [46]. For example, the
formation of some lipoxins is mediated through as-
pirin acetylated PGHS-2 in endothelial cells and
5-lipoxygenase in leukocytes [47]. The role of li-
poxins, in particular, appears to be centered upon
the resolution phase of the inflammatory process,
playing an inhibitory role on polymorphonuclear cell
adhesion and chemotaxis. Lipoxins tend to inhibit
formation of leukotriene B4, a primary mediator of
inflammatory cellular processes centered on re-
cruitment of polymorphonuclear cells from post-
capillary venules and their adhesion to endothelial
cells [46, 48]. Furthermore, lipoxin-mediated en-
hancement of TGF-b serves as a cue to further pro-
mote the resolution of fibrosis [46].
During the later stages of the inflammatory
process, signals from prostaglandins E2 and D2 trig-
ger the resolution mechanism necessary for the
recall of blood granulocytes. The mechanism con-
sists of enhancing the formation of the omega-3 fatty
acid-derived resolvins through independent EPA
and DHA pathways [49]. After an insult, these ad-
ditional mediators allow for endothelium homeosta-
sis to return. In a similar fashion to lipoxin produc-
tion, resolvin formation is heavily influenced by the
role of aspirin-mediated acetylation of the COX-2
enzyme [46, 50].
Aspirin-triggered lipoxins when used in an in
vivo animal model promote inflammation resolution,
apparently by shortening the maximal neutrophil
number present during the inflammatory response.
Resolvin E1 reduces the maximal neutrophil num-
ber and the time when this effect occurs [51]. Both
lipoxins and resolvins seem to act through concomi-
tant increase in the tissue repair and wound heal-
ing molecule TGF-b. Tissue repair and leukocyte
infiltration is of key importance at the endothelial
level, because macrophage incorporation and subse-
quent foam cell transformation plays a central role
in the pathogenesis of atherosclerotic plaque forma-
tion [52]. Given this, it is believed that potent lipid
mediators such as lipoxins and resolvins reduce the
process of leukocyte rolling and transmigration and
thus potentially attenuate the formation of athero-
sclerotic plaque on the vascular endothelium.
The role of lipoxins and resolvins has already
been evaluated in apoprotein E-deficient mice with
global leukocyte 12/15-lipoxygenase deficiency
[53]. Expression of the 12/15-lipoxygenase was
shown to be a protective mechanism against athe-
rosclerosis, suggesting its lipoxin A4 and resolvin
D1 products may be the mediators by which this
protection is conferred. In the same study, treat-
ment of human aortic endothelial cells with resolvin
D1 led to a significant decrease in MCP-1 and IL-8,
and a significant upregulation of the anti-inflamma-
tory compound PDGF-b. Lipoxin A4 in turn was
found to downregulate p-selectin expression. In
another study [54], diminution of leukocyte trans-
migration was also found in choroid-retinal endo-
thelial cell and leukocyte co-cultures, where addi-
tion of resolvin E1 and resolvin D1 not only de-
creased the number of leukocyte transmigrating
past the endothelial layer, but also diminished
IL-8, protein 1b and TNF-a.
Lastly, thrombus formation after endothelial
plaque rupture could potentially be attenuated by
these compounds. Using intravital microscopy and
a murine animal model, Dona et al. [55] showed that
in vivo administration of resolvin effectively reduc-
es leukocyte rolling by 40%. It was also reported
that resolvin E1 inhibits ADP and U46619 activat-
ed platelet aggregation in a concentration-depen-
dent manner. These effects are indicative of re-
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solvin’s ability to reduce platelet aggregation and
leukocyte-specific biochemical and structural pro-
cesses that allow for homing, rolling, and migration
across the endothelium.
Research suggests that resolvin E1 binds with
high affinity to the G-protein coupled chemerin re-
ceptor (ChemR23) [56, 57] present in monocytes,
macrophages, dendritic and endothelial cells. De-
spite recent evidence indicating the presence of
ChemR23 receptors on endothelial cells [58], to
date no studies have been published directly inves-
tigating the relationship between resolvins and
Chem23 receptors or their effects on the endothe-
lium. In other cells, RvE1 binding counter-regulates
TNF-a-stimulated NF-kB activation and enhances
macrophage phagocytosis of polymorphonuclear
cells via Akt and ribosomal subunit rS6 downstream
phosphorylation [59]. Lower binding affinity has also
been reported between resolvins and the BLT-1
(leukotriene B4 receptor 1) present on neutrophils.
It is possible, however, that these potent lipid me-
diators act through a series of receptors and path-
ways, and that additional targets remain to be iden-
tified on the endothelial cell surface.
Taken together, these findings suggest that
atherosclerotic plaque formation is affected by
a failure of the inflammation resolution mechanism
through which potent lipid mediators act on vascu-
lar endothelial cells to achieve homeostasis. Potent
lipid mediators, such as resolvins and lipoxins, may
serve as potential novel therapeutic agents to atten-
uate ongoing inflammatory processes within the vas-
cular endothelium. Even more intriguingly, exoge-
nous administration of these and similar potent lipid
mediators may even work as alternatives for indi-
viduals unable to obtain biochemical benefit from
aspirin’s anti-platelet effects. It could also be that the
ingestion of EPA and DHA will lead to a sufficient
quantity of the potent lipid mediators required for the
activation of these mechanisms, at least in most in-
dividuals at high risk for CVD.
Diagnostic modalities for assessment of en-
dothelial function might include local vasodilation
by venous occlusion plethysmography, flow-media-
ted dilatation, arterial pulse wave analysis, pulse
amplitude tonometry, microvascular bloodflow by
laser Doppler flowmetry, biochemical markers,
measurement of endothelial-derived microparti-
cles progenitor cells, and glycocalyx measure-
ments. These should advance the early detection
of vascular endothelial dysfunction before the
manifestation of serious adverse vascular or car-
diovascular disorders.
Conclusions
The stage is set for the rise of novel, long-term
risk reduction CVD therapies with regard to the
endothelium. Nitrates with supplementary anti-oxi-
dant effects such as pentaerithrityl tetranitrate are
likely ready for human safety trials, and dietary ni-
trite may also be deserving of such research. These
are basic ways of restoring some NO activity, and
this logically would have a good chance of reducing
the occurrence of long-term CVD development.
With regard to thrombomodulin, devising
a method for localized expression would open the
door to a much greater understanding of its ability
as a potential therapy. Again, these attempts may
include higher efficiency gene transfer methods, or
even less invasive forms of creating reduced flow
conditions, i.e. a meshwork (to slow flow) angioplas-
ty device which at the peak of inflation releases
a TM gene transfer vehicle. In addition, functional
assays and subsequent clinical testing of various
soluble thrombomodulin fragments just may open
the door to a superior breed of anti-coagulant mo-
lecules. TFPI also presents itself as a possible play-
er in this respect. Given the significant risks of
thrombosis and re-occlusion in current angioplasty
techniques, TFPI can have a role in localized reduc-
tion in risk of intimal thickening [23]. Perhaps stents
secreting TFPI can prevent the initial TF cascade
from inducing smooth muscle cell proliferation, and
therefore reduce the long-term re-occlusion risk.
The idea of exploring the clinical potential of
long-term low dose prostacyclin analogs seems
plausible as well. Just as ACEIs and ARBs are used
to protect the vasculature and renal system in hy-
pertensive states, perhaps prostacyclin can be
a well-tolerated protector of those with impaired en-
dothelial function. These analogs, along with ligus-
trazine derivatives, may turn out to be molecules
of great tolerability that can be used as a long-term
hedge against accelerated endothelial cell dysfunc-
tion in high risk patients. Furthermore, the evi-
dence is growing for the direct clinical utility of ilo-
prost in the settings of critical limb ischemia, war-
ranting larger and more controlled trials to assess
its efficacy and tolerability.
The elucidation of further drug targets such as
Nrf2, KLF2, and Sirt-1 opens the door for new com-
pounds to be created as agonists or antagonists of
these factors. Animal experimentation involving
chemical modulation of these entities may shed fur-
ther light on the favorability of these pathways for
human clinical applications.
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This review is an outline of some emerging
therapies centered mainly upon the preservation of
endothelial cell function. With scientific efforts con-
tinually plowing forward, perhaps CVD therapy will
soon be revolutionized. In time, CVD may cease to
be looked at as a treatable condition that is identi-
fied after much of its damage is done, but instead
as a syndrome preventable through the stabilization
of the endothelium.
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